These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 1870202)

  • 1. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.
    McKeating J; Balfe P; Clapham P; Weiss RA
    J Virol; 1991 Sep; 65(9):4777-85. PubMed ID: 1870202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
    Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
    J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients.
    Ghetie V; Slaughter C; Wheeler HT; Uhr JW; Vitetta ES
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5690-3. PubMed ID: 2062847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    Moore JP; McKeating JA; Huang YX; Ashkenazi A; Ho DD
    J Virol; 1992 Jan; 66(1):235-43. PubMed ID: 1727487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.
    Wyatt R; Thali M; Tilley S; Pinter A; Posner M; Ho D; Robinson J; Sodroski J
    J Virol; 1992 Dec; 66(12):6997-7004. PubMed ID: 1279195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.
    Willey RL; Martin MA; Peden KW
    J Virol; 1994 Feb; 68(2):1029-39. PubMed ID: 7904656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
    Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
    J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.
    McKeating JA; Bennett J; Zolla-Pazner S; Schutten M; Ashelford S; Brown AL; Balfe P
    J Virol; 1993 Sep; 67(9):5216-25. PubMed ID: 7688820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4.
    Werner A; Levy JA
    J Virol; 1993 May; 67(5):2566-74. PubMed ID: 8474162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity.
    Thali M; Olshevsky U; Furman C; Gabuzda D; Li J; Sodroski J
    J Virol; 1991 Sep; 65(9):5007-12. PubMed ID: 1870209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.
    Pinter A; Honnen WJ; Tilley SA
    J Virol; 1993 Sep; 67(9):5692-7. PubMed ID: 7688827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    Ly A; Stamatatos L
    J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.
    Thali M; Furman C; Helseth E; Repke H; Sodroski J
    J Virol; 1992 Sep; 66(9):5516-24. PubMed ID: 1501286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA; Saunders C; Hensel M; Stamatatos L
    J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
    Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
    J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deamidation of soluble CD4 at asparagine-52 results in reduced binding capacity for the HIV-1 envelope glycoprotein gp120.
    Teshima G; Porter J; Yim K; Ling V; Guzzetta A
    Biochemistry; 1991 Apr; 30(16):3916-22. PubMed ID: 2018763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
    J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
    J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.